Anixa director buys 10,000 shares at $2.73

Anixa Biosciences Inc (ANIX) director Lewis H. Titterton Jr. reported purchasing 10,000 shares of common stock on September 10, 2026 in an open-market or private transaction at $2.73 per share.

Rhea-AI Filing Summary

Anixa Biosciences Inc (ANIX) director Lewis H. Titterton Jr. reported purchasing 10,000 shares of common stock on September 10, 2026 in an open-market or private transaction at $2.73 per share. Following this purchase, he directly holds 996,967 shares of Anixa Biosciences common stock. No Rule 10b5-1 trading plan is reported for this transaction.

Insider Trade Summary

Net Buyer: 10,000 shares

Net Buy 1 txn

Insider Titterton Lewis H jr

Role Director

Bought 10,000 shs ($27K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	10,000	$2.73	$27K

Holdings After Transaction: Common Stock — 996,967 shares (Direct)

Key Figures

Shares purchased: 10,000 shares Purchase price per share: $2.73 per share Holdings after transaction: 996,967 shares

3 metrics

Shares purchased 10,000 shares Common stock acquired by director on September 10, 2026

Purchase price per share $2.73 per share Price paid for ANIX common stock on September 10, 2026

Holdings after transaction 996,967 shares Total ANIX common stock directly owned by the director after the purchase

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ANIX report for Lewis H. Titterton Jr.?

Lewis H. Titterton Jr., a director of Anixa Biosciences, reported purchasing 10,000 shares of common stock on September 10, 2026 in an open-market or private transaction at $2.73 per share.

How many ANIX shares does Lewis H. Titterton Jr. own after this transaction?

After the September 10, 2026 purchase, Lewis H. Titterton Jr. directly owns 996,967 shares of Anixa Biosciences common stock.

Was the ANIX insider share purchase made under a Rule 10b5-1 plan?

No. The report indicates that the September 10, 2026 purchase of 10,000 ANIX shares by director Lewis H. Titterton Jr. was not made under a Rule 10b5-1 trading plan.

What price did the ANIX director pay per share in the reported transaction?

In the transaction dated September 10, 2026, Anixa Biosciences director Lewis H. Titterton Jr. paid $2.73 per share for 10,000 shares of the company’s common stock.

Is the ANIX insider transaction a purchase or a sale?

The reported transaction is a purchase. On September 10, 2026, director Lewis H. Titterton Jr. acquired 10,000 ANIX shares of common stock in an open-market or private transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 09:15 AM Accepted by SEC EDGAR 09/14/2026 - 09:15 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Titterton Lewis H jr

(Last) (First) (Middle)

C/O ANIXA BIOSCIENCES, INC.

3150 ALMADEN EXPRESSWAY, SUITE 250

(Street)

SAN JOSE CALIFORNIA 95118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Anixa Biosciences Inc [ ANIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/10/2026		P		10,000	A	$2.73	996,967	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Lewis H. Titterton, Jr.	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)